BMGen is continuously developing its core technologies and methods for both sequencing and preclinical oncology services, and to seek ways to serve our customers better. BMGen actively participates in both national and international research consortia projects, mainly in the field of preclinical oncology.

Most recently BMGen has been involved with the National Board of Technology and Innovation (Tekes) and privately funded program “The personalized therapy, and drug development for breast cancer with living tumor samples” and in the Innovative Medicines Initiative (IMI) program “New Models for Preclinical Evaluation of Drug Efficacy in Common Solid Tumors”.

The personalized therapy, and drug development for breast cancer with living tumor samples program is a national partnership between two Finnish Universities, SMEs and a Finnish pharmaceutical company. The project focuses on biomaterials in breast cancer organoid cultures, with the goal of finding new solution and innovations for the needs of personalized medicine.

BMGen is one of the 21 partners collaborating in IMI-PREDECT, one of the major Innovative Medicines Initiatives (IMI) of the European Union. PREDECT has the overarching goal of comparing the pathological and molecular profiles of novel in vitro platforms with those of human tumors. BMGen specifically focuses on a platform development with patient derived breast cancer organoids.

kuvituskuva-2-2